Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
about
Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian settingCurrent developments in molecular monitoring in chronic myeloid leukemiaTyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trSelecting the best frontline treatment in chronic myeloid leukemiaTyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaMolecular response in CML: where is the bar?Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaPonatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibThe Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaAnalysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesAssessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.Current management of chronic myeloid leukemia with tyrosine kinase inhibitors.Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.Short overview on the current treatment of chronic myeloid leukemia in chronic phaseMolecular techniques for the personalised management of patients with chronic myeloid leukaemia.Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.Management of the new patient with CML in chronic phase.Chronic myeloid leukemia: overview of new agents and comparative analysis.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia.Molecular monitoring.Treatment recommendations for chronic myeloid leukemiaDefinition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.A review of the European LeukemiaNet recommendations for the management of CML.Response-related predictors of survival in CML.Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.Present and future of molecular monitoring in chronic myeloid leukaemia.The Role of Early Molecular Response in the Management of Chronic Phase CML.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib.
P2860
Q27008389-187574D8-60AE-412C-BA4E-87D2D21C82C1Q28066148-C9201341-C34C-497B-969C-4AC935B285BFQ28075963-6D2417EC-C1E3-4B5F-8908-FE7E4CFF8EFEQ31033077-FA63E6C6-F922-4D06-B66E-13538A05F9BAQ33764253-840F4B69-8408-465D-B989-42A331E64032Q33806617-2A36FBE3-7801-45F2-A43C-AC36ADB10406Q33948671-49607769-22D7-4537-B9D0-ABFC7D6E4AC7Q34022596-2F5B9E0A-3495-4A9E-9D7D-CCC228049BCEQ34155213-43746D01-FAF2-4D44-9FE3-81A871D3AD79Q34272962-04500FC8-B93B-44D6-B2B1-4FFC11D2B090Q34310190-A41514D8-BA44-4A0B-BA29-5EE45A26D0E7Q34644820-FC3314C7-FCBC-47A9-9153-040558A97643Q36104098-FFD4F0CA-267E-41B3-9099-E056ACB21ED1Q36219723-4C632A71-2F03-4319-8A50-BAD9A4A0EEF0Q36547224-062050C8-F095-4735-8A62-E85A5D26B151Q36734508-803E0FF4-7802-48C9-A15D-ADC63611C118Q36894983-FD310181-1A90-48CA-9D16-50DFA0774A13Q37026032-7BE535B6-4FBD-4BD6-B91E-930FE59A4EDEQ37095355-C305F24F-2F6F-435F-8A59-B46C7CBA98DAQ37273161-EEAED804-340F-42CC-AEAC-08F64813AE0AQ37426573-30385D35-9A52-4CFC-B4FB-94D46E5B0C91Q37427140-20F8EAD9-933A-4F84-8141-2B6C545BE8ABQ37512201-E6796ADF-90AC-43E3-BD73-AF0CBA4BC786Q37696776-4BB4D360-7515-4D16-8923-742208A71168Q38057413-DF440554-7CBF-4EC4-A889-BBEFA2137A3EQ38079151-339E3032-03BC-48AB-93F5-5155D1633571Q38097728-735A30A3-6B4D-408F-8237-418D29E00FE1Q38128723-77600D37-D33C-4554-A2DA-75EA550C3218Q38148233-1A7CFFB7-31D9-4451-9692-6AEED5CEE74AQ38154292-8B3380C6-E0F7-4624-BDA3-24E9C6E122E6Q38176284-F4B6BF98-511D-4AA1-862A-714A425BF16CQ38181112-D926B05B-67EF-4518-BBD2-FA91403A403AQ38199143-8987FA10-50F0-4C7B-9AFE-3486EAF81718Q38392676-08F42B30-945A-490C-9C3E-567703871A17Q38392705-2089724B-7A33-4515-8F3E-795CD0A2919FQ38685803-DD53577B-EAB3-42CA-AFDB-67579A90A9DFQ38762631-10CA4700-C9C7-462F-8B1C-C2EC6792EFA5Q39239805-4575061B-17FC-4F50-B13F-2260342CC130Q39457369-D9F4ED4B-2E7B-461D-B7DE-593C31EA96A5Q41578421-766FED44-3DC1-4B35-8162-B2764731D43D
P2860
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Predictive value of early mole ...... ted with first-line dasatinib.
@en
Predictive value of early mole ...... ted with first-line dasatinib.
@nl
type
label
Predictive value of early mole ...... ted with first-line dasatinib.
@en
Predictive value of early mole ...... ted with first-line dasatinib.
@nl
prefLabel
Predictive value of early mole ...... ted with first-line dasatinib.
@en
Predictive value of early mole ...... ted with first-line dasatinib.
@nl
P2093
P921
P1433
P1476
Predictive value of early mole ...... ted with first-line dasatinib.
@en
P2093
Christopher Pocock
Corinne Hedgley
David Marin
Dragana Milojkovic
Jane Apperley
John M Goldman
Letizia Foroni
Richard E Clark
Stephen O'Brien
P304
P356
10.1182/BLOOD-2012-01-407486
P407
P577
2012-05-29T00:00:00Z